CURRENT PUBLICATIONS LABORATORY RESEARCH miR-9, a MYC/MYCN-Activated MicroRNA, Regulates E-Cadherin and Cancer Metastasis MicroRNA-9, which is upregulated in breast cancer cells, directly targets CDH1, the E-cadherin-encoding messenger RNA, leading to increased cell motility and invasiveness. [Nat Cell Biol] Bitter Melon (Momordica charantia ) Extract Inhibits Breast Cancer Cell Proliferation by Modulating Cell Cycle Regulatory Genes and Promotes Apoptosis Researchers used human breast cancer cells, MCF-7 and MDA-MB-231, and primary human mammary epithelial cells as an in vitro model to assess the efficacy of bitter melon (Momordica charantia) extract as an anticancer agent. [Cancer Res] Negative Feedback Control of HIF-1 Through REDD1-Regulated ROS Suppresses Tumorigenesis Resarchers demonstrate a negative feedback loop for regulation of HIF-1 by REDD1, which plays a key role in tumor suppression. [Proc Natl Acad Sci USA] Complex Display of Putative Tumor Stem Cell Markers in the NCI60 Tumor Cell Line Panel Researchers investigated expression of putative cancer initiating cells surface markers and the activity of aldehyde dehydrogenase in the NCI60 panel singly and in combination by six-color FACS analysis. [Stem Cells] Antineoplastic Effects of an Aurora B Kinase Inhibitor in Breast Cancer Results define a novel mechanism for posttranscriptional regulation of Aurora B after AZD1152 treatment and provide insight into dosing regimen design for this kinase inhibitor in metastatic breast cancer treatment. [Mol Cancer] Potentiation of TNF-(Alpha)-Induced Tumor Cell Apoptosis by a Small-Molecule Inhibitor for Anti-Apoptotic Protein hPEBP4 Data suggest that IOI-42, as the first chemical inhibitor of anti-apoptotic protein hPEBP4, may serve as a potential antitumor drug by sensitizing tumor cells to apoptotic inducers. [J Biol Chem] Ataxia Telangiectasia Mutated (ATM) Inhibition Transforms Human Mammary Gland Epithelial Cells In MCF-10A and MCF-12A cells, partial or almost complete stable ataxia telangiectasia mutated silencing or pharmacological inhibition resulted in cellular transformation, genomic instability and formation of dysplastic lesions in NOD/SCID mice. [J Biol Chem] Exploring the Gain of Function Contribution of AKT to Mammary Tumorigenesis in Mouse Models To investigate the mechanistic basis of the AKT gain of function-dependent mechanisms of breast tumorigenesis, researchers explored the phenotype induced by activated AKT transgenes in a quantitative manner. [PLoS ONE] Nuclear Entry of Activated MAPK Is Restricted in Primary Ovarian and Mammary Epithelial Cells In primary cultures of breast and ovarian epithelial cells, phosphorylation and activation of ERK1/2 are disassociated from nuclear translocalization and transcription of downstream targets, such as c-Fos, suggesting that nuclear translocation is limited in primary cells. [PLoS ONE] CLINICAL RESEARCH HER2, TOP2A, and TIMP-1 and Responsiveness to Adjuvant Anthracycline-Containing Chemotherapy in High-Risk Breast Cancer Patients To evaluate whether the combination of HER2 with TIMP-1 or TOP2A with TIMP-1 more accurately identifies patients who benefit from cyclophosphamide, epirubicin, and fluorouracil compared with cyclophosphamide, methotrexate, and fluorouracil than these markers do when analyzed individually. [ J Clin Oncol] First-Line Trastuzumab Plus Epirubicin and Cyclophosphamide Therapy in Patients with Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Cardiac Safety and Efficacy Data From the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) Trial A high incidence of congestive heart failure has been observed in patients with metastatic breast cancer receiving doxorubicin-based chemotherapy and trastuzumab. The trial evaluated trastuzumab plus cyclophosphamide and the less cardiotoxic anthracycline epirubicin. [J Clin Oncol] Prospective Multicenter Cohort Study to Refine Management Recommendations for Women at Elevated Familial Risk of Breast Cancer: The EVA Trial Researchers investigated the respective contribution (in terms of cancer yield and stage at diagnosis) of clinical breast examination, mammography, ultrasound, and quality-assured breast magnetic resonance imaging, used alone or in different combination, for screening women at elevated risk for breast cancer. [J Clin Oncol] Cyclophosphamide, Methotrexate, and Fluorouracil; Oral Cyclophosphamide; Levamisole; or No Adjuvant Therapy for Patients with High-Risk, Premenopausal Breast Cancer The Danish Breast Cancer Cooperative Group 77B trial examined the relative efficacy of levamisole, single-agent oral cyclophosphamide, and the classic combination of cyclophosphamide, methotrexate, and 5-fluorouracil against no adjuvant systemic therapy in high-risk breast cancer patients. [Cancer]
|